RELEASE DATE: February 6, 2024

Moexa’s Cancelex brand confirms US Process Patent have been granted for our TGFß SMAD3 Inhibitor technology. The initial award is for treatment of lung carcinoma and melanoma specifically, with further coverage for any related therapeutic analogs making use of our technology.

This important grant secures our global patent library in major markets — including China, Europe and India— with a global population footprint of more than 5 billion people. Our IP covers 11 specified cancers that have a collective annual value of US$103 billion worldwide for related therapeutics.

Our strong IP library confirms the novelty of our technology: our downstream small molecule MoA prevents phosphorylation of SMAD3 and binding of the active SMAD2/3 heterotrimer before the complex enters the nucleus where cancer seeding germinates. In-vivo studies confirm our primary therapeutic effects eliminates tumors, retards tumor growth, and boosts NK cell development, without evidence of the side-effects and toxicity profiles historically associated with TGFß therapeutic solutions.

Moexa’s is prepared to commence IND protocols before a follow-on business development partnership with a top 5 CRO which will subsequently launch and co-manage first-in-human trials in Australia and Asia.

Parties interested in investment or further collaborations may contact us for more information. www.moexa.com
info@moexa.com

About Moexa

Moexa’s is a pre-clinical biotech with offices in Asia and US, and with a clinical lab in the US. We have created New Chemical Entities (NCE’s) prepared for Initial New Drug (IND) protocols. We plan to initiate First-in- Human trials with a top 5 listed CRO partner upon completion of IND. We have secured pledged funding to launch clinical trials, even as we are seeking capital partners interested in supporting IND before trials.

We have secured a global patent library covering all major markets, and with expanding coverage to secondary markets. Our fibrosis IP is similarly established, with new and ongoing R&D supported by a leading Ivy League research centre. The current population footprint of our anticancer IP captures more than 5 billion people, with 11 specified cancers and a collective annual therapeutic market value of US$103 billion worldwide for related cancer products.

Our small molecule inhibitors target the TGF-β SMAD3 pathway downstream. This technology was originally developed with US$32m in funding, including US$17m in NIH grants. The key MoA deactivates SMAD3 by inhibiting phosphorylation of SMAD2/3 and preventing seeding of the active heterotrimer complex well known to promote both cancer and fibrosis.

Our Pre-IND in-vivo anti-cancer studies indicate dose dependent efficacy, with the added benefit of Increasing NK cell proliferation, induced cancer apoptosis, reduced Treg cells mediated cancer tolerance, reduced CD31, VEGF mediated angiogenesis, and reduced MMP-2, -9, -13 CXCR4 mediated matrix degradation. These anti-cancer benefits have been observed without toxicity profiles previously associated with TGF-β products.

We welcome discussions on partnerships, collaborations, or investment with suitable qualified and accredited parties.

Please Contact Us Directly For More Information